DE60223524D1 - Verfahren zur vorbeugung von zelltod unter verwendung von antikörpern gegen neural thread proteine - Google Patents

Verfahren zur vorbeugung von zelltod unter verwendung von antikörpern gegen neural thread proteine

Info

Publication number
DE60223524D1
DE60223524D1 DE60223524T DE60223524T DE60223524D1 DE 60223524 D1 DE60223524 D1 DE 60223524D1 DE 60223524 T DE60223524 T DE 60223524T DE 60223524 T DE60223524 T DE 60223524T DE 60223524 D1 DE60223524 D1 DE 60223524D1
Authority
DE
Germany
Prior art keywords
antibody
ntp
deod
antibodies
cell death
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60223524T
Other languages
English (en)
Inventor
Paul A Averback
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nymox Corp Canada
Nymox Corp
Original Assignee
Nymox Corp Canada
Nymox Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nymox Corp Canada, Nymox Corp filed Critical Nymox Corp Canada
Application granted granted Critical
Publication of DE60223524D1 publication Critical patent/DE60223524D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE60223524T 2001-05-04 2002-05-06 Verfahren zur vorbeugung von zelltod unter verwendung von antikörpern gegen neural thread proteine Expired - Lifetime DE60223524D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28846301P 2001-05-04 2001-05-04
PCT/CA2002/000681 WO2002089841A2 (en) 2001-05-04 2002-05-06 Method of preventing cell death using antibodies to neural thread proteins

Publications (1)

Publication Number Publication Date
DE60223524D1 true DE60223524D1 (de) 2007-12-27

Family

ID=23107207

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60223524T Expired - Lifetime DE60223524D1 (de) 2001-05-04 2002-05-06 Verfahren zur vorbeugung von zelltod unter verwendung von antikörpern gegen neural thread proteine

Country Status (10)

Country Link
US (1) US20030003445A1 (de)
EP (1) EP1387698B1 (de)
JP (1) JP2004528367A (de)
KR (1) KR20040029968A (de)
CN (1) CN1635906A (de)
AT (1) ATE378069T1 (de)
AU (1) AU2002308327B2 (de)
CA (1) CA2446480A1 (de)
DE (1) DE60223524D1 (de)
WO (1) WO2002089841A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160361380A1 (en) * 2015-06-12 2016-12-15 Nymox Corporation Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187158A (en) * 1982-05-18 1993-02-16 University Of Florida Brain-specific drug delivery
US4880816A (en) * 1982-05-18 1989-11-14 University Of Florida Brain-specific delivery of dopamine utilizing dihydropyridine/pyridinium salt-type redox carriers
US5017566A (en) * 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
US5948634A (en) * 1988-12-21 1999-09-07 The General Hospital Coporation Neural thread protein gene expression and detection of alzheimer's disease
ATE145285T1 (de) * 1988-12-21 1996-11-15 Gen Hospital Corp Nachweis einer neurologischen krankheit oder einer funktionsstörung
KR20000075748A (ko) * 1997-02-26 2000-12-26 마빈 씨. 구트리 알츠하이머 병의 치료 또는 예방에 유효한 약물을 선별하기 위한 유전자 변형동물 및 세포계
AU8269898A (en) * 1997-06-27 1999-01-19 Regents Of The University Of California, The Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor
DE60222745T2 (de) * 2001-03-08 2008-07-10 Nymox Pharmaceutical Corp., St. Laurent Verwendung von neurofilamentproteinen zur behandlung von tumoren
US6770797B2 (en) * 2001-06-01 2004-08-03 Rhode Island Hospital Non-Transgenic nonhuman model for Alzheimer's Disease using a AD7c-NTP nucleic acid

Also Published As

Publication number Publication date
WO2002089841A2 (en) 2002-11-14
EP1387698A2 (de) 2004-02-11
JP2004528367A (ja) 2004-09-16
KR20040029968A (ko) 2004-04-08
WO2002089841A3 (en) 2003-04-24
ATE378069T1 (de) 2007-11-15
CN1635906A (zh) 2005-07-06
US20030003445A1 (en) 2003-01-02
AU2002308327B2 (en) 2006-11-30
EP1387698B1 (de) 2007-11-14
CA2446480A1 (en) 2002-11-14

Similar Documents

Publication Publication Date Title
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
ATE305779T1 (de) Behandlung cytokin-vermittelter krankheiten mit tec familie protein tyrosin kinase inhibitoren
DE60319364D1 (de) Substituierte pyrroline als kinase inhibitoren
ATE298566T1 (de) Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
ATE441418T1 (de) Verwendung von treprostinil zur verbesserung der nierenfunktion
ATE322290T1 (de) Verwendung von cyclooxygenase-2 inhibitor celecoxib und capecitabine zur kombinationsbehandlung von neoplasia
RU2013131640A (ru) Способы мониторинга модуляции киназной активности рецептора фактора роста фибробластов и применения указанных способов
NO963860L (no) Isoprenyl-transferase-inhibitorer
ATE399007T1 (de) Raf kinase hemmer
BR9910511A (pt) Tratamento de tumores humanos com radiação einibidores de tirosina cinases receptoras de fatorde crescimento
DE60323749D1 (de) Substituierte pyrroline als kinase inhibitoren
DE69629578D1 (de) Verwendung von wenigstens einem no-synthase hemmer zur behandlung empfindlicher haut
ATE250932T1 (de) Verfahren zur behandlung von chronischem schmerz durch verabreichung von einem mek hemmer
DK1237575T3 (da) TNF-alfa-antagonist og LFA-1-antagonist til behandling af rheumatoid arthritis
BRPI0415395A (pt) composto, métodos para inibir a atividade da proteìna quinase e para tratar um paciente que tenha uma condição que seja mediada pela atividade da proteìna quinase, e, composição
ATE303162T1 (de) Natrium kanalblocker zusammensetzungen und deren verwendung
ATE538781T1 (de) Neue verwendung von peptidverbindungen zur behandlung von dyskinesie
DE60227709D1 (de) Die verwendung von c-kithemmern zur behandlung von autoimmunerkrankungen
ATE411018T1 (de) Verfahren zur behandlung oder verhinderung von vaskulärer entzündung mit sterol-absorbierungs- inhibitor(en)
HK1080092A1 (en) Vegf antagonists for the treatment of diabetes
ATE315939T1 (de) Verfahren zur prophylaxe oder kontrolle des katarakts
ATE554169T1 (de) Smad7-inhibitoren zur behandlung von krankheiten des zns
DE60327557D1 (de) Verwendung von spongosin (2-methoxyadenosin) zur behandlung von schmerzen, insbesondere hyperalgesie
HK1060851A1 (en) Preventing cell death using segments of neural thread proteins.
DE60223524D1 (de) Verfahren zur vorbeugung von zelltod unter verwendung von antikörpern gegen neural thread proteine

Legal Events

Date Code Title Description
8332 No legal effect for de